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CONCISE COMMUNICATION
CD4 T cells remain the major source of HIV-1 during
end stage disease
Marchina E. van der Endeab, Martin Schuttena, Birgit Raschdorffc,
Gudrun Großschupffc Paul Raczc, Albert D.M.E. Osterhausa
and Klara Tenner-Raczc
Objective: To assess the source of HIV-1 production in lymphoid tissue biopsies
from HIV-infected patients, with no prior anti-retroviral protease inhibitor treatment,
with a CD4 cell count > 150 · 106/l (group I) or < 50 · 106/l (group II), co-infected
with Mycobacterium tuberculosis or Mycobacterium avium complex.
Design and methods: Lymphoid tissue biopsies from 11 HIV-1-infected patients,
taken for diagnostic purposes, were studied by HIV-1 RNA in situ hybridization and
immunohistochemistry.
Results: Patients of group I showed well organized granulomas, in contrast with
patients of group II, in which granuloma formation was absent. HIV-1 RNA-positive
cells in group I patients were found mainly around the granulomas, whereas in
group II HIV-1-producing cells were confined to areas with remaining intact
lymphoid tissue. Despite the abundant presence of macrophages, the productively
infected HIV-1-positive cells in both groups were almost exclusively CD4 T cells.
Conclusion: In contrast with previously published data, CD4 T cells appear to
remain the major source of HIV-1 production in end-stage disease.
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Introduction
Molecular histopathological studies of lymphoid and
non-lymphoid tissues of HIV-1-infected individuals
have contributed considerably to our knowledge of the
mechanisms involved in HIV-1-induced disease. Soon
after infection, when HIV-1-specific humoral and 
cellular immune responses can be demonstrated, virus
production is confined largely to CD4 T cells located
within lymphoid tissues such as lymph nodes, mucosa
associated lymphoid tissue and spleen [1–4]. During the
entire asymptomatic stage of the disease, CD4 T cells
are the major source of HIV-1, whereas productively
infected cells expressing macrophage or dendritic cell
markers are observed rarely in lymphoid tissues.
Productively infected macrophages and dendritic cells
have been observed in nasopharyngeal lymphoid tis-
sues, cervix and brain [5–10]; however, these cells are
generally believed to contribute minimally to the high
levels of virus produced throughout the course of the
infection. During the asymptomatic and early sympto-
matic stages (CD4 cell count > 200 · 106/l), follicular
hyperplasia with irregularly shaped follicles are often
observed [11,12]. Large numbers of virus particles
within immune complexes are then captured onto the
processes of follicular dendritic cells [1,2].
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In the intermediate stages of the infection, the numbers
of productively infected CD4 T cells within lymphoid
tissue increase [1,2]. Ultimately however CD4 T cells
almost disappear and the architecture of lymphoid 
tissue, especially with regard to the germinal centres
and the follicular dendritic cells network, is disrupted
and the ability to trap virus is lost. Also at this stage of
the disease, virus production is relatively high [13]. The
increase of cell-free plasma HIV RNA and the virtual
absence of CD4 T cells, which are thought to be the
major source of virus production, is until now an unre-
solved paradox. Recently it has been suggested by
Orenstein et al., that a possible explanation may be a
switch from CD4 T cells to another cell type as the
major source of virus during end-stage disease [14]. An
alternative explanation could be that due to the
increased replication rate of HIV-1 at end-stage disease,
as well as a higher percentage of infected cells, a small
reservoir of CD4 T lymphocytes is sufficient to 
produce the observed increased levels of cell-free virus
in plasma [15].
To address this issue we studied lymphoid tissue biop-
sies from 11 HIV-1-infected patients co-infected with
Mycobacterium tuberculosis (MTB) or M. avium complex
(MAC), by HIV-1 RNA in situ hybridization and
immunohistochemistry. Patients co-infected with MTB
or MAC were selected because their lymphoid tissue
generally contains large numbers of macrophages. The
hypothesis of Orensetin et al., that at end-stage disease
the bulk of HIV-1 production shifts from CD4 T cells
to macrophages may be tested by studying these
patients.
Material and methods
Patient materials
Lymph node specimens taken from eleven HIV-1-
seropositive patients for diagnostic purposes, were
selected for this study. The selection criteria were:
HIV-1 laboratory diagnosis; MTB or MAC laboratory
diagnosis; peripheral blood CD4 T cell count < 500 ·
106/l or AIDS-defining disease; no prior anti-retroviral
therapy with protease inhibitors. The peripheral blood
CD4 cell counts and co-infections are listed in Table 1.
Immunohistochemistry
Tissues were fixed overnight with 4% buffered formalin
(pH 7) and subsequently embedded in paraffin. The tis-
sues were cut for routine histology (Giemsa,
Ziehl–Neelsen, haematoxylin & eosin and Gomori’s
silver impregnation). For immunohistochemistry,
dewaxed 5 µm paraffin sections were placed in a
domestic pressure cooker containing 0.01 M sodium
citrate solution (pH 6), boiled for 2 min, and chilled to
room temperature [16]. Primary antibodies against
CD4 (Novocastra, Newcastle upon Tyne, UK), CD68
(KP1), lysozyme and CD45RO (UCHL-1) (Dakopatts,
Copenhagen, Denmark) were used as described previ-
ously [17]. The sections were subsequently either
counter-stained with haematoxylin & eosin and
mounted, or they were dehydrated and subjected to
HIV RNA in situ hybridization.
In situ hybridization
A 35S-labelled, single stranded, anti-sense HIV-1 RNA
probe (Lofstrand Labs., Gaithersburg, Maryland, USA),
which contains 1.4–2.7 kb fragments collectively repre-
senting approximately 90% of the HIV-1 genome, was
used as previously described [3]. In short, paraffin 
sections were either treated with proteinase K 
(0.01 mg/ml) for 8 min. at room temperature or heat
denatured in citrate buffer (pH 6). The sections were
incubated with prehybridization mixture (50% 
formamide, 0.5 M NaCl, 10 mM Tris–HCl (pH 7.4), 
1 mM EDTA, 0.02% Ficoll–polyvinylpyrrolidone–BSA
and 7 mg tRNA/ml) for 2 h at 37°C and then covered
with hybridization mixture (prehybridization mixture
supplemented with 10% dextran sulphate and 2 · 106
d.p.m. of probe/ml) overnight at 45°C. The sections
were washed, RNAse treated (Boehringer Mannheim
GmbH, Mannheim, Germany) for 40 min at 37°C,
rewashed and then dipped into emulsion (NTB2;
Kodak, Rochester, New York, USA). After exposure
for 3–7 days the slides were developed, counter-stained
with haemalaun and mounted as described previously.
As negative controls, sections were hybridized with a
radiolabelled sense probe. The sections were examined
with a microscope equipped with epiluminescent illu-
mination (Axiophot, Carl Zeiss Inc., Jena, Germany).
Cells were considered positive for viral gene expression
if the number of grains counted was more than six
times the number in the background.
Table 1. Clinical characteristics of 11 HIV-1-seropositive patients.
Patient CD4 T cells · 106/l Co-infection
Group Ia
1 427 MTB
2 440 MTB
3 300 MTB
4 200 MTB
5 170 MTB
Group IIa
6 < 50 MTB
7 < 50 MTB
8 < 50 MAC
9 < 50 MAC
Undefineda
10 ND MTB
11 ND MTB
aGroup I, Patients with CD4 cell count 50–500 · 106/l; Group II,
patients with CD4 T cell count < 50 · 106/l. ND, Not done; MTB,
Mycobacterium tuberculosis. MAC, M. avium complex.
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Results
Lymph nodes from patients with 150–500 · 106
peripheral CD4 T cells/l, hereafter referred to as group
I patients, contained multiple well organized granulo-
mas occupying 50–90% of the cutting surface. In parts
of the tissue that were not involved in the granuloma
formation, the nodal architecture with T cell depen-
dent zone and several small inactive germinal centres
was preserved. The granulomas were composed of
epitheloid cells, multinucleated cells of the Langhans’-
type and CD4 as well as CD8 T lymphocytes. The
central part of the granulomas often showed caseation
(data not shown). In contrast, in lymph nodes from
patients with peripheral CD4 T cell counts < 50 ·
106/l, hereafter referred to as group II patients, well
organized granulomas were absent. The nodal architec-
ture was obscured by a heavy confluent infiltrate 
consisting of macrophages, intermingled with reactive
plasma cells. The macrophages contained many acid-
fast bacilli. The number of CD4 T lymphocytes was
decreased; they were present only in the remnants of
lymphoid tissue seen as small islets at the periphery of
the lymph nodes or between the bands of macrophages
(Fig. 1a).
In the lymphoid tissues from the group I patients, the
number of HIV-1 RNA-positive cells was unevenly
distributed. Significant numbers of cells with a heavy in
situ hybridization overlay were observed mainly around
the granulomas and occasionally within the granulomas
(Fig. 1b). The numbers of HIV RNA-positive cells
within the parts of the nodes where granulomas were
observed, were approximately 10 fold higher than
those in lymphoid tissue areas that did not contain
granulomas (data not shown). In lymphoid tissues from
end stage disease patients (group II), the numbers of
HIV-1 RNA-positive cells were not significantly
increased as compared to lymphoid tissue areas where
no infiltrate of macrophages was observed. HIV-1-
producing cells were confined to areas with remaining
lymphoid tissue (Fig. 1a).
The phenotype of the productively HIV-1-infected
cells was subsequently determined by double-labelling
of HIV RNA by in situ hybridization and immunohis-
tochemical staining for CD4, CD45RO, CD68 or
lysozyme. Despite the abundant presence of
macrophages and Langhans’-type giant cells, the HIV
RNA-positive cells in the lymphoid tissues from
patients of group I proved to be almost exclusively
CD45RO+CD68–lysozyme– (Fig. 1b, insert I, d),
identifying them as CD4 T cells. The HIV-1 RNA-
positive cells in lymphoid tissues from end stage disease
patients (group II) also proved to be CD4 T cells.
Occasionally an HIV-1 RNA+CD45+CD68+
lyzosyme+ cell was observed (Fig. 1d), excluding the
possibility that productively HIV-1-infected
Fig.1. HIV-1 in situ hybridization on lymph nodes co-infected with Mycobacteria. (a) One MAC-infected lymph node from a
HIV-1-infected patient No.8. The HIV-1 RNA signal (arrow) is present only in areas with some intact lymphoid architecture
(original magnification · 40). (b) A M. tuberculosis infected lymph node (patient No.1) with considerable numbers of CD4 T
cells (red), and a significantly higher number of HIV-1 RNA-positive cells (arrows); the inset (I) shows double-staining of HIV-1
RNA and CD45RO-positive cells (original magnification · 400). (c) Abundant numbers of macrophages (red) did not corre-
spond with HIV-1 RNA-positive cells (arrows). (d) Occasionally an HIV RNA+CD68+lysozyme+ cell was observed (arrow).
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macrophages were not identified due to down-
regulation of CD68 and lysozyme expression by HIV-1
infection. Furthermore, the in situ hybridization grain
counts of HIV-1 RNA-positive CD4 T cells were 
generally much heavier than those on HIV-1 RNA-
positive macrophages, suggesting a lower level of virus
production in the latter (Fig. 1c,d).
Discussion
We have shown that in contrast to previously pub-
lished data, CD4 T cells remained the major source of
HIV-1 production at end stage infection. The histolog-
ical appearance and cellular composition of granulomas
in lymphoid tissue from group I patients did not differ
from those seen in immunocompetent patients [18].
Granuloma formation is characteristic in the cell medi-
ated immune response to MTB, and it is well estab-
lished that CD4 T cells play a pivotal role in host
defence against intracellular microorganisms [18].
Around the granulomas massive HIV-1 production was
mainly confined to CD4 T cells. This finding is in
agreement with the observed increase of the non-cell
associated plasma viral load during opportunistic infec-
tions [19,20] and in studies on lymphoid tissue from
HIV-1-infected patients co-infected with opportunistic
organisms [14]. Treatment of opportunistic or bacterial
infections in HIV-1-infected patients resulted again in a
decrease of plasma viral load levels to the levels
observed before the onset of the opportunistic infection
[19–21]. The abundant presence of macrophages in
lymphoid tissue from both groups did not apparently
contribute to the viral load. Not only was the number
of HIV-1 RNA-positive infected macrophages low,
but also the level of in vivo virus production by
macrophages, assessed by in situ hybridization grain
counting, was lower than in CD4 T cells. In addition,
in in situ double labelling analyses of biopsies collected
from 50 lymphatic tissues of more than 50 individuals
at different stages of HIV-1 infection, productively
infected macrophages have been observed only scarcely
(unpublished observations). Considering the observa-
tion that at end-stage disease, in approximately 50% of
patients so-called X4/syncitium inducing/rapid-high
HIV-1 strains arise, which have shown to be less
macrophage-tropic as compared with HIV-1 strains
isolated from asymptomatic individuals [22,23], we
postulate that at end stage disease CD4 T cells, rather
than macrophages, remain the major source of HIV-1
production. Whether these clearly conflicting observa-
tions with previously published data [14] may attribute
to differences in patient selection or laboratory tech-
niques remains to be determined. The paradox of
increasing viral loads with progressively declining cir-
culating CD4 T cells therefore remains. We and others
[24–26] have, however, recently shown that in patients
with low peripheral CD4 T cells the decrease of tissue
CD4 T cell count is slower. It may be assumed that
patients with CD4 T cell counts < 50 · 106/l, still have
sufficient numbers of CD4 T cells to allow the produc-
tion of the high viral loads generally observed in such
patients. Recent studies in AIDS patients have shown a
sharp increase of the peripheral blood CD4 T cell
count after starting highly active antiretroviral therapy
[26,27], probably reflecting redistribution of CD4 T
cells from epitheloid organs such as the lung or the gut.
Taking into account the increased percentage of pro-
ductively infected cells and the increased virus replica-
tion rate of HIV-1 strains isolated, it seems likely that
also at the end stage of the disease sufficient CD4 T
cells are present in the individual to explain the high
viral load observed.
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